Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Crosses Above 200 Day Moving Average – Here’s What Happened

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $44.26 and traded as high as $44.27. Global X Genomics & Biotechnology ETF shares last traded at $43.86, with a volume of 5,529 shares changing hands.

Global X Genomics & Biotechnology ETF Trading Up 0.4%

The firm’s 50-day simple moving average is $46.93 and its 200 day simple moving average is $44.26. The stock has a market cap of $47.81 million, a P/E ratio of -18.74 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Announces Dividend

The firm also recently disclosed a dividend, which was paid on Wednesday, January 7th. Stockholders of record on Tuesday, December 30th were given a dividend of $0.5912 per share. The ex-dividend date was Tuesday, December 30th. This represents a dividend yield of 259.0%. Global X Genomics & Biotechnology ETF’s payout ratio is currently -26.50%.

Institutional Trading of Global X Genomics & Biotechnology ETF

Large investors have recently added to or reduced their stakes in the business. IFP Advisors Inc boosted its position in Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after acquiring an additional 489 shares during the period. Creative Financial Designs Inc. ADV increased its holdings in shares of Global X Genomics & Biotechnology ETF by 4.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after purchasing an additional 481 shares during the period. U.S. Capital Wealth Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at $575,000. Smartleaf Asset Management LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after purchasing an additional 4,615 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.